BALTIMORE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Generex Biotechnology Corp. (GNBT), an emerging, diversified health care provider, announced today that Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors has released a new research report and CEO interview. The report carries a price target. To view the new research report, listen to the interview, along with viewing disclosures and disclaimers, or to download them in their entirety, please visit http://www.goldmanresearch.com.
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development. The Company's direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care. Generex's management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care. The Company also is engaged in clinical advancement of its wholly owned therapeutic products with a focus in immunotherapeutics and its proprietary buccal administration of insulin.
In the Opportunity Research report, analyst Rob Goldman discusses the Company's compelling positioning, exciting opportunities, and innovative approach.
Goldman noted, "Generex could go from also-ran to a firm generating revenue at an annual revenue run-rate of over $100 million. The Company just closed on an acquisition that has generated $100M or more annually in recent years and is primed to grow dramatically as it begins to offer its services in 30 states, versus 3 this year."
"Generex plans to become a diversified health care firm that utilizes cash from its high growth M&A targets to help fund its R&D in the areas where an unmet need exists. These include diabetes, breast cancer, prostate cancer and others. The Company is also collaborating with a Canopy Growth-invested firm to explore using one of its delivery system offerings for medical marijuana patients in Canada."
"Generex announced a 20:1 stock dividend with a record date of Friday While there is likely to be a re-adjustment in share price as a result, the current market capitalization, compared with its likely revenue next year (via M&A) and underlying value of its portfolio, appears to be at a major discount. As more deals are closed, major value could be unlocked in the coming months," commented Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored company research report on LandStar, Inc. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Generex Biotechnology Corp. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download the research report, audio interview or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was not compensated for research, interview or distribution services, including the production of this press release.
About Generex Biotechnology Corp.: Generex Biotechnology Corp. (GNBT) is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development. The Company's direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care. Generex's management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care. The Company also is engaged in clinical advancement of its wholly owned therapeutic products with a focus in immunotherapeutics and its proprietary buccal administration of insulin.
For more information, please visit: www.Generex.com
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com